David Phillips
10qdetective
David J. Phillips, a contributing editor to Fool.com, is a former equity analyst. He holds an MBA from Boston College.
Recent Articles by David Phillips
Mar 27, 2014
by David Phillips
Can AbbVie's Legacy Products Deliver Further Growth?
AbbVie is spending more than 16% of annual sales to develop new drugs that will lesson the drug maker's dependence on the rheumatoid arthritis drug Humira. Fortunately, the Chicago-based drug manufacturer has a stable of off-patent, legacy drugs that contribute sizable sales to this R&D effort.
Mar 8, 2014
by David Phillips
AbbVie's Humira Still a Growth Engine
A published survey of rheumatologists suggests that growth in key European markets for AbbVie’s (NYSE: ABBV) flagship drug Humira could stall as biosimilar options become more prevalent. Absent longer-term safety data on these follow-on drugs, Humira should continue to shine.
HOW THE MOTLEY FOOL CAN HELP YOU
-
Premium Investing Guidance
Market beating stocks from our award-winning service
-
The Daily Upside Newsletter
Investment news and high-quality insights delivered straight to your inbox
-
Get Started Investing
You can do it. Successful investing in just a few steps
-
Win at Retirement
Secrets and strategies for the post-work life you want.
-
Find a Broker
Find the right brokerage account for you.
-
Listen to our Podcasts
Hear our experts take on stocks, the market, and how to invest.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.